GE rolls out new animal-free hMSC growth medium with cost saving claim

By Gareth Macdonald

- Last updated on GMT

Related tags Cell culture Stem cell

GE rolls out new animal-free hMSC growth medium
GE Healthcare has launched a new cell culture medium that it claims will let manufacturers skip lengthy validation steps and achieve greater batch to batch consistency.

The new medium – Xuri MSC – is intended for the expansion of human mesenchymal stem cells (hMSC), which are used by researchers to makecartilage, bone and fat cells. hMSC cells are being tested in a number of therapeutic applications, from lupus and stroke​ to brain cancer​ and Crohn’s disease​.

Phil Vanek, General Manager for Cell Therapy Technologies, GE Healthcare Life Sciences, told one of the biggest advantages the new medium has over others used to culture hMSC is that it is free of animal products.

Traditionally cell culture is carried out in media that needs to be supplemented with animal serum. There are challenges around batch to batch variability of serum as well as supply chain and logistical challenges, which means validation and risk assessment is required for each batch.

Our serum-free and xeno-free medium removes this need for validation requirement, maintaining consistent cultivation results between batches.”

Process efficiency

Vanek also claimed the new medium can benefit manufacturers from a production efficiency and facility space utilisation perspective.

He explaining that: “it can expand cells to the high numbers required for therapeutic doses without the high variability of conventional serum-based medium systems and can achieve higher cell yield compared to serum facilitated cultures.

The medium also enables the growth of MSCs in a very compact way on surfaces which accounts for the higher cell yield. This becomes far more important for bioreactor facilitated scale up where getting the most cells on the smallest volume possible is a crucial step in industrialization of process development.”

The Launch of the new medium comes just a few weeks​ after GE completed its acquisition of Thermo Fisher Scientific’s Hyclone culture media business.

Related news

Show more

Related products

show more

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Related suppliers

Follow us


View more